Sapra A, Bhandari P
L-karnitin Kilo Vermeye Yardmc Olur Mu
Common reactions include nausea, constipation, dizziness, insomnia, and headache, particularly during the dose-escalation phase
All statistical procedures were performed using SPSS 27.0 software and an alpha level of 0.05 was set for all statistical measures
Dose Group GI Adverse Events (%) Nausea (%) Abdominal Discomfort/Pain Placebo 32.6% 11.6% Low baseline 1 mg 48.6% ~20% Mild, infrequent 4 mg (escalated) 60.0% ~30% Moderate increase 8 mg (escalated) 57.5% ~38% Present in dose-escalation phase 12 mg (escalated) 66.7% 45.8% Highest incidence, mostly transient Source: Jastreboff AM, Kaplan LM, Fras JP, et al
Specification: 70MG This product is intended for laboratory and research purposes only